QP-Prostate®

Quibim

QP-Prostate®

Improving cancer detection through AI technology

CE marked, 510(k) cleared, and UKCA marked.

Discover QP-Prostate®

Prostate cancer ranks as the second most prevalent cancer in men, posing a significant public health concern.
While MRI scans are vital for early detection, the increased demand for scans has outpaced the growth of radiology experts. This has resulted in diagnostic delays and inconsistent interpretations, with only a minority of the medical community adhering to PI-RADS v2.1 guidelines.

Introducing QP-Prostate, an AI-powered solution designed to streamline radiologists' workflows. By automatically evaluating compliance against PI-RADS v2.1 guidelines, segmenting the prostate gland, and identifying suspicious lesions, QP-Prostate empowers radiologists to deliver quicker and more accurate assessments, ultimately enhancing patient care.

Introducing a suite of enhanced diagnostic capabilities

Fully Automated Workflow

Ensure consistent and seamless incorporation of all outputs from QP-Prostate into your hospital's PACS with no disruptions to radiologists' workflow.

AI-based automated lesion detection

Our AI algorithm, trained with pathology data, is designed to accurately and rapidly detect clinically significant prostate cancer lesions using biparametric data (T2W and DWI). These algorithms are intended to elevate diagnostic accuracy with automated detection of aggressive prostate cancer lesions.



Precision in segmentation

Our software segments the prostate gland with market-leading accuracy (88%)[1]. It segments three key subregions (Peripheral, Transitional+Central zones, and Seminal Vesicles), includes PI-RADS v2.1 regions, and computes prostate volume, facilitating fusion biopsy planning.

AI-QUAL™: Automated prostate image quality assessment

Quibim's AI-QUAL automates the assessment of prostate MRI image quality based on the PI-QUAL v2 guidelines. This tool streamlines workflows and supports diagnostic confidence.

AI-QUAL 1



AI-QUAL 3



Changing the narrative in prostate diagnostics

Experience confident, intelligent, and reliable prostate MRI interpretation with QP-Prostate – your trusted solution providing comprehensive insights and precise assessments for better patient care and outcomes.

The product will be enhanced with predictive capabilities in upcoming versions, which are currently undergoing clinical studies for imaging-based prediction of biochemical relapse. Recent studies show that combining MRI with clinical data predicts a 10-year biochemical recurrence with an area under the curve (AUC) of 0.84 to 0.87[2].

[1] Jimenez-Pastor A, et al. Eur Radiol. 2023;33(7):5087-5096.
[2] Sánchez Iglesias Á, et al. Cancers (Basel). 2023;15(16):4163.



Clinical cases using QP-Prostate®

Clinical Case 01

65 YO BIOPSY PATIENT WITH PSA: 5,1 NG/ML.

THE RADIOLOGIST DETECTS 3 LESIONS:
- L1 In the right anterolateral region of the medial gland, transition zone (PI-RADS 4).
- L2 In the right posterolateral region, peripheral zone (PI-RADS 3).
- L3 In the left posterolateral region of the apex, peripheral zone (PI-RADS 3).

QP-PROSTATE DETECTS 2 LESIONS:
- L1 Highly suspicious.
- L2 No lesion.
- L3 Moderately suspicious.

TARGETED BIOPSY CONFIRMS 2 LESIONS:
- L1 Gleason score 4+3.
- L2 Benign prostatic tissue.
- L3 Gleason score 3+4.



Clinical Case 02

74 YO BIOPSY PATIENT WITH PSA: 15 NG/ML.

THE RADIOLOGIST DETECTS 1 LESION:
- L1 in the middle gland peripheral zone, posteromedial/lateral area (PI-RADS 4).

QP-PROSTATE DETECTS 1 LESION:
- L1 No lesion.
- L2 Suspicious lesion.

TARGETED BIOPSY CONFIRMS 1 LESION:
- L1 Benign prostatic tissue.
- L2 Gleason score 4+3.



Clinical Case 03

69 YO BIOPSY PATIENT WITH PSA: 5 NG/ML.

THE RADIOLOGIST DETECTS 1 LESION:
- L1 (PI-RADS 3, DCE+; PI-RADS 4).

QP-PROSTATE DETECTS 0 LESIONS:
- L1 No lesion.

TARGETED BIOPSY CONFIRMS 0 LESIONS:
- L1 Benign prostatic tissue.



Quibim

Contact us: sales@quibim.com
US: +1 201-290-6110 / EU: +34 961 243 225